Clesacostat
- Generic Name
- Clesacostat
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
- Conditions
- Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 75
- Registration Number
- NCT04399538
- Locations
- 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸Excel Medical Clinical Trials, Boca Raton, Florida, United States
🇺🇸Optimus U Corporation, Miami, Florida, United States
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
- Conditions
- NAFLD (Nonalcoholic Fatty Liver Disease)NASH (Nonalcoholic Steatohepatitis)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Columbia University
- Registration Number
- NCT04395950
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
- Conditions
- Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis With Liver Fibrosis
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT04321031
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸United Medical Doctors, Murrieta, California, United States
🇧🇬DCC Mladost-M Varna OOD, Varna, Bulgaria
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT03597217
- Locations
- 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03448172
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03309202
- Locations
- 🇸🇰
Univerzitná Nemocnica Bratislava, Bratislava, Slovakia
🇨🇿Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰Summit Clinical Research s.r.o., Bratislava, Slovakia
Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
- Conditions
- Nonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 305
- Registration Number
- NCT03248882
- Locations
- 🇨🇦
Discovery Clinical Services Ltd., Victoria, British Columbia, Canada
🇺🇸South Denver Gastroenterology, P.C., Englewood, Colorado, United States
🇺🇸ClinSearch, Chattanooga, Tennessee, United States
Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 96
- Registration Number
- NCT02871037
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.